Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-05-08
1997-09-16
Gerstl, Robert
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514326, 514364, 546209, 548136, 548143, 548144, A01K 3141, C07D28512, C07D27110
Patent
active
056681593
ABSTRACT:
##STR1## This invention relates to improved isoxazoline compounds including, but not limited to 1,3,4-thiadiazoles and 1,3,4-oxadiazoles of the formula which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex, to pharmaceutical compositions containing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.
REFERENCES:
patent: 5482966 (1996-01-01), Bird
Confalone Pasquale Nicholas
Jin Fuqiang
Gerstl Robert
The DuPont Merck Pharmaceutical Company
LandOfFree
1,3,4-thiadiazoles and 1,3,4-oxadiazoles as IIb/IIIa antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as IIb/IIIa antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as IIb/IIIa antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-218677